Diversity & Expertise in Clinical Study Performance
"We have worked with NOVUM for almost 25 years and several items remain consistent throughout that time; best in class science, top notch communication and impeccable quality. I believe many of us in the industry have come to trust Novum with both our routine and extremely difficult studies. When looking for a true CRO partner, Novum comes to mind first".
-VP, Global Generic Clinical R&D
Clinical Trials Division has a broad therapeutic scope in Phases II-IV
Approximately 200 Early Phase studies conducted per year
Scientists Advancing Affordable Medicines, Inc. Presented its 2018 Inaugural Workshop: Streamlining Generic Drug Development by Matching Reference Product Composition and Performance, In Vitro and In Vivo on October 18th & 19th, 2018 in Baltimore, MD. Novum’s Chief Scientific Officer Dr. Keith Gallicano is the co-founder of this organization.
Trust 40-plus years of industry experience.
Novum is a full-service CRO with numerous FDA approvals in ANDA and NDA submissions. We conduct more than 250 studies a year across multiple therapeutic areas and have developed long-standing relationships with a wide range of global sponsors who rely on our Early Phase Research and Clinical Trial Management expertise.
There are plenty of ways to get in touch. Just select the one that is best for you.
Novum prides itself on its talented and dedicated team of employees. The Novum team is passionate about customer satisfaction, safety and study integrity. All Novum clinical staff members receive extensive training designed to continually hone and increase the skills of each employee.
Want to participate in a study?
Last year we paid over $6.6 million to participants of our research studies.